Physician profile
William Harper
NPI 1518960707
$4,153.17
in general payments reported to CMS, 2019-2025
33 companies · $521 in 2025
The $521 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $364 · 2021: $422 · 2022: $606 · 2023: $707 · 2024: $1,116 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $616.01 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $502.72 | 2019-2024 | Xiaflex |
| Myriad Genetic Laboratories, INC. | $489.16 | 2021-2025 | Prolaris, Myrisk |
| Astellas Pharma US INC | $406.69 | 2019-2025 | Xtandi, Veozah |
| Boston Scientific Corporation | $328.97 | 2020-2024 | Ams 700, Spaceoar Vue System - 10ml, Rezum Generator |
| Abbvie INC. | $300.70 | 2019-2025 | |
| Axonics, INC. | $277.09 | 2021-2024 | Axonics |
| Janssen Biotech, INC. | $155.58 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $142.76 | 2023-2025 | Orgovyx, Gemtesa |
| Merck Sharp & Dohme LLC | $122.60 | 2022-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Endo USA, INC. | $109.93 | 2024-2025 | Xiaflex |
| Myovant Sciences INC. | $72.90 | 2021-2022 | |
| Medtronic, INC. | $69.17 | 2021-2023 | Interstim |
| Teleflex LLC | $64.28 | 2023-2024 | Urolift |
| Olympus America INC. | $48.42 | 2024 | Itind System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $46.13 | 2024-2025 | Jatenzo, Eligard |
| Angiodynamics, INC. | $44.34 | 2022 | |
| Medtronic USA, INC. | $42.96 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $39.08 | 2023-2024 | Pylarify |
| Travere Therapeutics, INC. | $31.92 | 2020-2021 | |
| Henry Schein, INC. | $31.53 | 2024 | |
| Sun Pharmaceutical Industries INC. | $24.89 | 2022 | |
| Rochester Medical Corporation | $22.42 | 2020 | |
| Allergan, INC. | $19.50 | 2019 | |
| Coloplast Corp | $19.49 | 2022 | |
| Dendreon Pharmaceuticals LLC | $17.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.37 | 2023 | |
| Sagent Pharmaceuticals | $16.87 | 2019 | |
| Amgen INC. | $15.57 | 2022 | |
| Metuchen Pharmaceuticals | $15.57 | 2020 | |
| Laborie Medical Technologies Corp. | $15.57 | 2020 | |
| Galderma Laboratories, L.P. | $13.44 | 2024 | |
| Urovant Sciences INC | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.